BioInvent International AB (OMXS: BINV), a Sweden-based clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, has extended the research term of its cancer immunotherapy research collaboration and license agreement with United States-based Pfizer Inc until the end of 2020, it was reported on Wednesday.
Both firms entered into a contract in December 2016 for the development and commercialisation of antibodies aimed at tumour-associated myeloid cells discovered using the company's proprietary FIRSTTM drug discovery platform. The aim of the research extension is to allow the firms to further identify and characterise new targets and antibodies binding to these targets.
In 2019 Pfizer selected the first and second target under the agreement, which triggered two payments from Pfizer to BioInvent of USD300,000. BioInvent is likely to be eligible for further milestone payments from development of antibodies directed against these targets and from the selection of additional targets and the development of antibodies directed against those targets.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886